575 related articles for article (PubMed ID: 23886432)
21. Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors.
Lee JH; Kim SC; Choi H; Jung CG; Ban GY; Shin YS; Nahm DH; Park HS; Ye YM
J Korean Med Sci; 2017 Jul; 32(7):1124-1130. PubMed ID: 28581269
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous immunotherapy with purified Der p1 and 2 suppresses type 2 immunity in a murine asthma model.
Hesse L; van Ieperen N; Habraken C; Petersen AH; Korn S; Smilda T; Goedewaagen B; Ruiters MH; van der Graaf AC; Nawijn MC
Allergy; 2018 Apr; 73(4):862-874. PubMed ID: 29318623
[TBL] [Abstract][Full Text] [Related]
23. [An analysis of skin prick test reactivity to dust mite in overweight and normal weight children with allergic asthma before and after specific immunotherapy].
Wang J; Huang Y; Zhang XL; Huang X; Xu XW; Liang FM
Zhongguo Dang Dai Er Ke Za Zhi; 2016 Apr; 18(4):329-34. PubMed ID: 27097578
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy.
Swamy RS; Reshamwala N; Hunter T; Vissamsetti S; Santos CB; Baroody FM; Hwang PH; Hoyte EG; Garcia MA; Nadeau KC
J Allergy Clin Immunol; 2012 Jul; 130(1):215-24.e7. PubMed ID: 22677046
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy and safety evaluation of Dermatophagoides farinae drops in the treatment of allergic rhinitis with epistaxis.
Pei J; Ding Z; Cai L; Yang H; Tao Y; Huang C
Eur Ann Allergy Clin Immunol; 2024 May; ():. PubMed ID: 38813925
[No Abstract] [Full Text] [Related]
26. Utility of silver birch and house dust mite extracts derived from licensed sublingual tablets for nasal allergen challenge.
Olivieri B; Gil AJ; Stoenchev K; Durham SR; Scadding G
Clin Transl Allergy; 2024 May; 14(5):e12360. PubMed ID: 38779783
[TBL] [Abstract][Full Text] [Related]
27. Clinical Relevance of Lepidoglyphus destructor Sensitisation in Allergic Rhinitis: Nasal Provocation Test as in vivo Assessment.
Matos Semedo F; Martins C; Tomaz E; Cardoso B; Farinha S; Martins M; Paula Pires A; Inácio F; Taborda-Barata L
Int Arch Allergy Immunol; 2024; 185(5):436-448. PubMed ID: 38266498
[TBL] [Abstract][Full Text] [Related]
28. Sodium Chloride versus Lactose as a Carrier for House Dust Mite Allergen in Allergen Chamber Studies: A Clinical Study to Assess Noninferiority.
Struß N; Dieter S; Schwarz K; Badorrek P; Hohlfeld JM
Int Arch Allergy Immunol; 2023; 184(11):1143-1152. PubMed ID: 37586347
[TBL] [Abstract][Full Text] [Related]
29. House dust mite sublingual allergen immunotherapy tablet is safe and well-tolerated in Dutch clinical practice.
Tempels-Pavlica Ž; Aarts MCJ; Welsing PMJ; van der Meer AN; van der Zwan LP; Uss E; Knulst AC
Front Allergy; 2024; 5():1355324. PubMed ID: 38487467
[TBL] [Abstract][Full Text] [Related]
30. Immune Cell Alterations and PI3K-PKB Pathway Suppression in Patients with Allergic Rhinitis Undergoing Sublingual Immunotherapy.
Zhang X; Wu G; Ma X; Cheng L
Adv Ther; 2024 Feb; 41(2):777-791. PubMed ID: 38169061
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis.
Stoelzel K; Bothe G; Chong PW; Lenarz M
Clin Respir J; 2014 Oct; 8(4):382-90. PubMed ID: 24279907
[TBL] [Abstract][Full Text] [Related]
32. Increased Nasal Blimp1 + Treg Cells After Sublingual Immunotherapy Reflect the Efficacy of Treatment in Allergic Rhinitis.
Pan Y; Zhang X; Geng H; Yu Y; Liu J; Li M; Yang H; Yuan Y; Xu Y; Wu Y; Wu G; Ma X; Cheng L
Adv Ther; 2024 Apr; 41(4):1698-1710. PubMed ID: 38443650
[TBL] [Abstract][Full Text] [Related]
33. Decreased Basophil Activation against House Dust Mite after Japanese Cedar Pollen Subcutaneous Immunotherapy: A Retrospective Study.
Inuo C; Ando H; Tanaka K; Nakajima Y; Tsuge I; Urisu A; Kondo Y
Int Arch Allergy Immunol; 2024; 185(1):73-78. PubMed ID: 37852197
[TBL] [Abstract][Full Text] [Related]
34. Progressive clinical effects of the combination omalizumab and HDM - allergen immunotherapy in asthma.
Bozek A; Rogala B; Miodonska M; Canonica GW
J Asthma; 2024 Jun; 61(6):532-538. PubMed ID: 38064236
[TBL] [Abstract][Full Text] [Related]
35. Tolerability of sublingual versus vestibular allergy immunotherapy tablet administration: A randomized pilot study.
Simard ML; Novak N; Drolet JP; Joly MC; Nolte H; Wuestenberg E; Gagnon R
Clin Exp Allergy; 2024 Feb; 54(2):120-129. PubMed ID: 37990117
[TBL] [Abstract][Full Text] [Related]
36. Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis.
Wang N; Song J; Sun SR; Zhu KZ; Li JX; Wang ZC; Guo CL; Xiang WX; Tong YL; Zeng M; Wang H; Xu XY; Yao Y; Liu Z
Allergy; 2024 May; 79(5):1230-1241. PubMed ID: 38403941
[TBL] [Abstract][Full Text] [Related]
37. Real-world assessment of anaphylaxis and eosinophilic esophagitis with 12 SQ house dust mite SLIT-tablet sublingual immunotherapy.
Zeiger RS; Schatz M; Pomichowski ME; Li Q; Slezak JM; Nolte H; Takhar HS
J Allergy Clin Immunol Glob; 2024 Aug; 3(3):100250. PubMed ID: 38699651
[TBL] [Abstract][Full Text] [Related]
38. Study on Effects of Sublingual Immunotherapy in Allergic Rhinitis Patients.
Patel K; Gupta N; Prajapati BJ; Prajapati A; Sharma S; Rathava D
Indian J Otolaryngol Head Neck Surg; 2023 Apr; 75(Suppl 1):804-808. PubMed ID: 37206799
[TBL] [Abstract][Full Text] [Related]
39. Satisfaction, Qol and adherence of patients allergic to dust mites and/or pollens undergoing sublingual immunotherapy.
Garrido-Fernández S; Fernández DG; López GS; Mar Escribano Rodríguez MD; Delgado VM; Iglesias-Souto J; Castro Gómez C; Bòria EV; Hernández-Peña J; Sánchez-López J
Immunotherapy; 2024 Jun; ():1-12. PubMed ID: 38888502
[TBL] [Abstract][Full Text] [Related]
40. Baseline Severity and Disease Duration Can Predict the Response to Allergen-specific Immunotherapy in Allergic Rhinitis.
Li Y; Xiao H; Zeng Y; Tang Y; Zhou L; Liu W
Iran J Allergy Asthma Immunol; 2024 Feb; 23(1):52-58. PubMed ID: 38485909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
